🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. HEC110114 tablet

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Hepatitis C

    phase 2 small molecule completed

    2 trials

  2. HEC121120 tablets

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  3. HEC169096

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  4. HEC585

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    5 trials

  5. HEC585 dose A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

    phase 2 small molecule active

    1 trial

  6. HEC96719

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  7. HPV DNA Plasmids Therapeutic Vaccine VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Anal Intraepithelial Neoplasia

    phase 2 mab completed

    1 trial

  8. HT-100

    Processa Pharmaceuticals

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    2 trials

  9. HYCAMTIN 4 mg powder for concentrate for solution for infusion, TAXOL 6 mg/ml, concentrato per soluzione per infusione., Neulasta 6 mg solution for injection, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion

    SUTRO BIOPHARMA, INC.

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 2 small molecule active

    1 trial

  10. HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE

    Novartis Pharmaceuticals

    relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

    phase 2 small molecule active

    1 trial

  11. HZN-1116, HZN-1116, commercially available 0.9% (w/v) saline solution intended for SC administration, HZN-1116

    Elan Pharma International

    Sjögren’s Syndrome

    phase 2 small molecule active

    1 trial

  12. HarMono-T 5 microlitres/mL gas and solvent for dispersion for injection/infusion

    Lacuna Pharma Pty Ltd

    Ultrasound contrast agent, for diagnostic purposes (to assess indeterminate kidney lesions)

    phase 2 small molecule active

    1 trial

  13. Homoharringtonine

    Teva Pharma GmbH

    Myeloid Leukemia, Chronic

    phase 2 small molecule terminated

    1 trial

  14. Humanized immunoglobulin G1 (IgG1) kappa monoclonal antibody (mAb) targeting PAUF

    Lacuna Pharma Pty Ltd

    Advanced and/or metastatic pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. Huperzine A, Huperzine A, Capsules, Huperzine A

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Onset Seizures

    phase 2 small molecule active

    1 trial

  16. Hyaluronidase

    Amphastar France Pharmaceuticals

    Allergic Skin Reaction

    phase 2 small molecule completed

    1 trial

  17. Hydroxychloroquine (HCQ)

    Teva Pharma GmbH

    COVID-19

    phase 2 small molecule terminated

    1 trial

  18. IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, Faslodex 250 mg solution for injection., JZP598

    Jazz Pharmaceuticals Ireland Limited

    Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive, HR-positive breast cancer

    phase 2 small molecule active

    1 trial

  19. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  20. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  21. IDARUBICIN, FLUDARABINE, CYTARABINE, DAUNORUBICIN, MITOXANTRONE, ETOPOSIDE, PKC412

    Novartis Pharmaceuticals

    untreated FLT3-mutated Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  22. IDOR-1117-2520 matching placebo

    Lacuna Pharma Pty Ltd

    Moderate to severe chronic plaque psoriasis

    phase 2 small molecule active

    1 trial

  23. ILT-101 liquide, Placebo of ILT-101

    Pari Pharma GmbH

    Autism Spectrum disorder ASD

    phase 2 small molecule active

    1 trial

  24. ILT-101 liquide, Placebo of ILT-101, CICLOSPORIN

    Pari Pharma GmbH

    Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources